Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Down 7.8% – What’s Next?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were down 7.8% during mid-day trading on Wednesday . The company traded as low as $676.71 and last traded at $674.4270. Approximately 885,633 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 734,401 shares. The stock had previously closed at $731.77.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a “sector perform” stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today’s weaker price action. Regeneron drops despite Q1 beat

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Royal Bank Of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a research report on Thursday. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $826.59.

Regeneron Pharmaceuticals Stock Down 0.8%

The stock has a market cap of $74.15 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.58 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.15 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average is $756.81 and its two-hundred day moving average is $735.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 3,774 shares of company stock valued at $2,942,738. Insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Regeneron Pharmaceuticals by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after purchasing an additional 26,884 shares during the last quarter. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after purchasing an additional 45,513 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares during the period. Nuveen LLC increased its stake in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares during the period. Finally, Capital World Investors lifted its stake in shares of Regeneron Pharmaceuticals by 1.6% in the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after acquiring an additional 32,348 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.